Durvalumab in DLBCL After Autologous Transplant

Summary

The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.

Timeline

Start

2017-10

Primary completion

2021-10

Completion

2021-12

Outcome

Outcome not reported

Stopped: “Celgene withdrew the support for this study (Durvalumab cannot be provided)”

Drugs

Indications